Latest News
Lion Biotechnologies signs worldwide license agreement with Moffitt Cancer Centre
29 July 2014 - It was reported yesterday that Lion Biotechnologies (OTCQB:LBIO), a biotechnology company that is developing novel cancer immunotherapies, has signed a worldwide license agreement with Moffitt Cancer Centre, an NCI-designated cancer hospital in Tampa, Florida.

According to the contract, Lion Biotechnologies has received license from Moffitt for the rights to develop and commercialise new technologies to improve tumour infiltrating lymphocytes production from melanoma. The company stated that the license is based on two provisional patent applications, filed under 'Compositions and Methods for Improving Tumor-Infiltrating Lymphocytes for Adoptive Cell Therapy.'

Lion chief scientific officer Laszlo Radvanyi said, 'This licensing agreement with Moffitt gives us access to technologies that may allow us to enhance TIL production from these tumors, thereby unlocking the potential of TILs to treat, and possibly cure, certain cancers beyond melanoma.'

Login
Username:

Password: